SVB's crystal ball points to big money biotech IPOs, downshift in the torrid pace of venture investing
It was a bang-up year for biopharmas in need of cash. Investors closed enormous funds in 2017, IPOs rolled out at a steady pace, and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
